timothy sykes logo

Stock News

Rani Stock Quintuples After Chugai Collaboration Announcement

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 10/18/2025, 9:16 am ET 10/18/2025, 9:16 am ET | 5 min 5 min read
Rani Stock Quintuples After Chugai Collaboration Announcement Thumbnail

Rani Therapeutics Holdings Inc. stocks have been trading up by 288.62 percent after promising developments and market optimism.

Healthcare industry expert:

Analyst sentiment – positive

Rani Therapeutics (RANI) currently finds itself in a precarious market position, as evidenced by its deeply negative profit margins, such as an EBIT margin of -4010.3% and a profit margin of -2473.83%. Despite a gross margin of 100%, the company’s decline in profitability highlights substantial operational inefficiencies. As of Q2 2025, Rani’s total liabilities ($26 million) significantly overshadow its assets ($16.9 million), revealing negative equity. These financial fundamentals indicate a struggling enterprise with operational and financial challenges requiring urgent attention. Although recent investments and expansions, indicated by a 3-year revenue growth, underscore the company’s potential for future growth, Rani nevertheless demands focused restructuring and capital management strategies for viability.

Technically, RANI’s recent price trends showcase a dominant bullish breakout, evidenced by a significant price surge on October 17. After trading in relatively low volatility ranges (0.46-0.49) in the days preceding, the stock’s leap to a close of 1.83 signals strong upward momentum. The spike in volume, associated with this breakout, confirms decisive institutional buying interest. A recommended trading strategy involves taking a long position following confirmed support at 1.50, accompanied by a tight stop loss slightly below this level, and setting a short-term target of 2.00 given the recent momentum and market interest.

Recent strategic moves by Rani Therapeutics, such as the collaboration with Chugai Pharmaceutical and a notable debt conversion and private placement, signify promising developments. The Chugai partnership potentially worth $1.085 billion portends significant future revenue streams and operational funding. The reduction in debt via equity conversion, paralleled by a private placement, enhances liquidity, optimizing Rani’s capital structure. Compared to industry benchmarks, Rani’s proactive financial maneuvers brighten its long-term prospects, with the company poised to leverage its innovative platform. Key resistance at 2.00 and support at 1.50 warrants monitoring. Overall, Rani Therapeutics’ outlook is undeniably improving, with recent strategic partnerships and financial restructuring indicating robust potential for recovery and growth, contingent on executing its innovation roadmap effectively.

Candlestick Chart

Weekly Update Oct 13 – Oct 17, 2025: On Saturday, October 18, 2025 Rani Therapeutics Holdings Inc. stock [NASDAQ: RANI] is trending up by 288.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Rani Therapeutics has recently shown dramatic fluctuations in its stock performance, with the closing price soaring from $0.47 on October 16, 2025, to a remarkable $1.83 just a day later. This sharp uptick can be attributed to the strategic collaboration with Chugai Pharmaceutical, which is poised to inject significant capital—up to $1.09 billion—into the development and commercialization of new medical technologies. This instantaneously propelled the stock upwards, reflecting a positive market sentiment.

Despite these promising developments, Rani’s profitability metrics depict substantial challenges. The EBIT margin stands at an exceptionally low -4,010.3%, indicating severe operational inefficiencies and high overhead costs relative to earnings. Profitability ratios such as the EBITDA margin also reflect immense room for improvement, with a figure of -3,760.30%.

Value assessments underscore the company’s current struggles, with a price-to-book ratio of -6.07, suggesting that market values the company’s assets far below their cost. However, gross margins remain at a full 100%, highlighting that potential profitability could be maximized by reducing overhead. The firm’s financial results indicate room for caution, yet the infusion of capital from this monumental deal could be the catalyst needed to steer Rani towards fiscal recovery.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”